Biotech Acquisition (BIOT) Short Interest Ratio & Short Volume

Short interest is the volume of Biotech Acquisition shares that have been sold short but have not yet been closed out or covered. As of January 15th, investors have sold 9,300 shares of BIOT short. 0.04% of Biotech Acquisition's shares are currently sold short. Learn More on Biotech Acquisition's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.04% of Biotech Acquisition's floating shares are currently sold short.

Biotech Acquisition saw a increase in short interest in January. As of January 15th, there was short interest totaling 9,300 shares, an increase of 1,228.6% from the previous total of 700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Biotech Acquisition currently has issued a total of 28,750,000 shares. Some of Biotech Acquisition's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Biotech Acquisition currently has a public float of 23,000,000 shares.

0.04% of Biotech Acquisition's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Biotech Acquisition: Kamada Ltd. (0.13%), Erasca, Inc. (9.88%), Akebia Therapeutics, Inc. (6.40%), Terns Pharmaceuticals, Inc. (10.92%), Enanta Pharmaceuticals, Inc. (13.94%), Aquestive Therapeutics, Inc. (3.10%), Inozyme Pharma, Inc. (6.27%), CorMedix Inc. (15.05%), XOMA Co. (2.36%), Vanda Pharmaceuticals Inc. (4.57%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($3.43 billion), T. Rowe Price Group, Inc. ($2.26 billion), Coinbase Global, Inc. ($2.19 billion), Etsy, Inc. ($1.78 billion), Paramount Global ($1.77 billion), Old Dominion Freight Line, Inc. ($1.69 billion), United Rentals, Inc. ($1.53 billion), American Airlines Group Inc. ($1.52 billion), PG&E Co. ($1.48 billion), and Voya Financial, Inc. ($1.47 billion). View all of the most shorted stocks.

Short selling BIOT is an investing strategy that aims to generate trading profit from Biotech Acquisition as its price is falling. BIOT shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Biotech Acquisition occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BIOT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BIOT, twice per month. The most recent reporting period available is January, 15 2023.